Jump-starting the immune system: Prime-boosting comes of age

Trends in Immunology

Volumn 25, Issue 2, 2004, Pages 98-104

  Woodland, David L ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7;

ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; DEFECTIVE VIRUS; FOWLPOX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSTIMULATION; INFECTION CONTROL; INFLUENZA VIRUS; LISTERIA MONOCYTOGENES; LUNG INFECTION; MEMORY CELL; MUCOSAL IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; PARAINFLUENZA VIRUS 1; PLASMODIUM; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0842324614     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.11.009     Document Type: Review

References (88)

1. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature. 406:2000;793-798.
2. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today. 21:2000;163-165.
3. Newman M.J. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr. Opin. Investig. Drugs. 3:2002;374-378.
4. McShane H. Prime-boost immunization strategies for infectious diseases. Curr. Opin. Mol. Ther. 4:2002;23-27.
5. + cytotoxic T lymphocyte population. Int. Immunol. 14:2002;31-37.
6. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69:2001;681-686.
7. Brooks J.V., et al. Boosting vaccine for tuberculosis. Infect. Immun. 69:2001;2714-2717.
8. Tanghe A., et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69:2001;3041-3047.
9. Feng C.G., et al. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69:2001;4174-4176.
10. Takeda A., et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a Macaque AIDS model. J. Virol. 77:2003;9710-9715.
11. Matano T., et al. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J. Virol. 75:2001;11891-11896.
12. Robinson H.L., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:1999;526-534.
13. Haglund K., et al. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J. Virol. 76:2002;7506-7517.
14. Amara R.R., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
15. + T cell responses. J. Immunol. 169:2002;4778-4787.
16. Amara R.R., et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76:2002;7625-7631.
17. Horton H., et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76:2002;7187-7202.
18. Shiver J.W., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335.
19. Gilbert S.C., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 20:2002;1039-1045.
20. Schneider J., et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine. 19:2001;4595-4602.
21. Bruna-Romero O., et al. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11491-11496.
22. Fensterle J., et al. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J. Immunol. 163:1999;4510-4518.
23. Gonzalo R.M., et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 20:2002;1226-1231.
24. Sullivan N.J., et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408:2000;605-609.
25. Sullivan N.J., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 424:2003;681-684.
26. Matsui M., et al. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 21:2003;1629-1639.
27. Pancholi P., et al. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. 77:2003;382-390.
28. Meseda C.A., et al. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 186:2002;1065-1073.
29. Eo S.K., et al. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166:2001;5473-5479.
30. van der Burg S.H., et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine. 19:2001;3652-3660.
31. Pancholi P., et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology. 33:2001;448-454.
32. Goonetilleke N.P., et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171:2003;1602-1609.
33. McConkey S.J., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9:2003;729-735.
34. Moorthy V.S., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine. 21:2003;1995-2002.
35. Hanke T., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine. 21:2002;108-114.
36. Fazekas de St G., Webster R.G. Disquisitions of original antigenic Sin. I. Evidence in man. J. Exp. Med. 124:1966;331-345.
37. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:1998;397-402.
38. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17:1999;51-88.
39. + T cell response to influenza A viruses. J. Immunol. 165:2000;2404-2409.
40. + T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J. Immunol. 160:1998;2425-2432.
41. + memory T cells specific for a subdominant epitope following Sendai virus infection. J. Immunol. 158:1997;4301-4309.
42. Harrington L.E., et al. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76:2002;3329-3337.
43. Sallusto F., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;708-712.
44. Sallusto F., et al. Functional subsets of memory T cells identified by CCR7 expression. Curr. Top. Microbiol. Immunol. 251:2000;167-171.
45. Lefrancois L., Masopust D. T cell immunity in lymphoid and non-lymphoid tissues. Curr. Opin. Immunol. 14:2002;503-508.
46. Masopust D., et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 291:2001;2413-2417.
47. Reinhardt R.L., et al. Visualizing the generation of memory CD4 T cells in the whole body. Nature. 410:2001;101-105.
48. + T cells that persist in the lungs. J. Exp. Med. 193:2001;981-986.
49. + T cells persist in the lungs following recovery from respiratory virus infections. J. Immunol. 166:2001;1813-1822.
50. Wherry E.J., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:2003;225-234.
51. + cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology. 254:1999;50-60.
52. Gallichan W.S., Rosenthal K.L. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184:1996;1879-1890.
53. Fynan E.F., et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U. S. A. 90:1993;11478-11482.
54. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:2003;337-339.
55. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:2003;339-342.
56. Tough D.F., Sprent J. Turnover of naïve- and memory-phenotype T cells. J. Exp. Med. 179:1994;1127-1135.
57. Schluns K.S., et al. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat. Immunol. 1:2000;426-432.
58. + memory T cells by opposing cytokines. Science. 288:2000;675-678.
59. Tough D.F., et al. Stimulation of memory T cells by cytokines. Vaccine. 18:2000;1642-1648.
60. Swain S.L., et al. Class II-independent generation of CD4 memory T cells from effectors. Science. 286:1999;1381-1383.
61. Murali-Krishna K., et al. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 286:1999;1377-1381.
62. + T-cell memory. Nat. Med. 7:2001;913-919.
63. Cauley L.S., et al. Cutting edge: virus-specific CD4(+) memory T cells in nonlymphoid tissues express a highly activated phenotype. J. Immunol. 169:2002;6655-6658.
64. + T cells in the lung airways depends on proliferation. J. Immunol. 169:2002;4976-4981.
65. Nakaya Y., et al. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine. 21:2003;2097-2106.
66. Barouch D.H., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 77:2003;8729-8735.
67. Gherardi M.M., et al. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J. Virol. 77:2003;7048-7057.
68. Hanke T., et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine. 20:2002;1995-1998.
69. Belyakov I.M., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:2003;9458-9463.
70. Kirman J.R., Seder R.A. DNA vaccination: the answer to stable, protective T-cell memory? Curr. Opin. Immunol. 15:2003;471-476.
71. Woodberry T., et al. Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias. J. Immunol. 170:2003;2599-2604.
72. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell. 111:2002;927-930.
73. + T cell responses and protection against Leishmania major infection. J. Exp. Med. 195:2002;1565-1573.
74. Tritel M., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol. 171:2003;2538-2547.
75. Heath W.R., Carbone F.R. Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 11:1999;314-318.
76. Xiang Z., Ertl H.C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 2:1995;129-135.
77. Palmowski M.J., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168:2002;4391-4398.
78. Hanke T., et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine. 17:1999;589-596.
79. + T cells. J. Immunol. 171:2003;1999-2005.
80. Kapikian A.Z., et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:1969;405-421.
81. + T cell memory. J. Immunol. 164:2000;3274-3282.
82. + T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 198:2003;399-410.
83. Belyakov I.M., et al. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102:1998;2072-2081.
84. Liang S., et al. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1994;1653-1661.
85. Belyakov I.M., et al. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4512-4517.
86. Cauley L., et al. Renewal of peripheral CD8 memory T cells during secondary viral infection of antibody sufficient mice. J. Immunol. 170:2003;5597-5606.
87. + T cells to the lung during influenza pneumonia. J. Immunol. 167:2001;6983-6990.
88. + T cells to the lung airways during respiratory virus infections. J. Immunol. 170:2003;1423-1429.